| INTRODUCTION
Coronary heart disease is the leading cause of death worldwide.
Almost 4 million men and 3.5 million women die of the disease each year. 1 The new field of cell-based therapy offers a complementary mode of treatment, in addition to coronary reperfusion, in patients with acute myocardial infarction (AMI) by replacing dysfunctional myocytes and improving heart function. 2, 3 Cell-based therapies promote tissue repair through the introduction of exogenous cells, such as bone-marrow (BM)-derived mesenchymal stem-cells, that may secrete paracrine factors, stimulate neovascularization, and activate cardiac regeneration.
These exogenous cells were traditionally derived from the BM, but recently, cells originating from adipose tissue, cardiospheres, and CD34+ cells have been utilized. Clinical trials, however, have revealed either no improvement or only modest improvement in heart function with stem-cell-based therapies applied to patients with AMI or an underlying cardiomyopathy. [4] [5] [6] [7] Finding the optimal type of stem-cell for cardiac cytoprotection and regeneration and introducing stem-cells at multiple time points after cardiac injury may improve clinical outcomes and optimize regenerative gains in heart function. 8 The cardioprotective effects of low-level laser therapy (LLLT) have been demonstrated in the ischemic heart in vivo and in vitro. 9, 10 In rat and dog models, LLLT application directly to ischemic myocardium at optimal power parameters significantly reduced myocardial scar tissue formation. [11] [12] [13] [14] Furthermore, in a rat model, LLLT application to autologous BM induced proliferation and recruitment of mesenchymal stem cells to the infarcted myocardium and markedly reduced scarring, while simultaneously inducing cardiogenesis along the border of the infarcted area. [15] [16] [17] [18] In a recent study using a porcine model of AMI, applying LLLT to the BM caused a significant reduction in myocardial scarring relative to non-laser treated pigs. 19 Furthermore, in the same study, the left ventricular ejection fraction (LVEF) in the laser treated pigs was found to be significantly higher than in the non-laser treated ones. 19 Despite these promising results in animal models, to the best of our knowledge, application of LLLT in human subjects has not yet been studied.
In patients presenting with ST-elevation myocardial infarction (STEMI), acute occlusion of an epicardial artery results in myocardial ischemia and infarction in the area subtended by the occluded artery.
Early reperfusion salvages viable myocardium, but despite this, a large proportion of patients develop left-ventricular dysfunction from irreversible cell death, reperfusion injury, and remodeling. LLLT
has not yet been applied to patients with STEMI but recruitment of 
| Chemical analysis
Blood samples were collected for leukocytes and platelet counts, as well as Troponin-T and Creatinphosphokinase (CPK) levels. The blood samples were collected at admission and 12-hour after admission and then daily for the next 5 days. After discharge, blood samples collected at 30 days and 9 months.
Serum was prepared from fresh blood and stored immediately at −70°C in small aliquots for determination of Troponin-T and CPK. For analysis was performed using standard hematological methods.
| Echocardiography
All patients were evaluated by two-dimensional echocardiography (Vivid E90, GE Healthcare) during the first 12 h, 1 month, and 9 months after STEMI. Regional left-ventricular function was assessed semiquantitatively according to the recommendations of the American Society of Echocardiography scoring scheme. 20 
| Laser treatment
We utilized the Tunable Ga-Al-As 808 nm wavelength diode laser with a 900 mW power output (Thore Photomedicine Ltd., England) in this study. The optimal laser power, frequency and timing for transmission through bone was ascertained from our previous experiments including our recent BM histological analysis after laser application to the tibia of the infarcted porcine model. 19 A rigid glass (metal backed) fiber optic (8 mm diameter) connected to a flexible glass fiber optic was used to deliver the energy from the laser unit to the patient's tibia. The laser was applied by contact of the distal tip of the rigid fiber optic with the external side of the tibia bones (non-invasive to the bone or the skin) to ensure optimal power density delivery (10 mW/cm 2 ) to the BM tissue (cells) within the bones. The first laser treatment was applied as soon as possible after admission and usually in the coronary angiography laboratory (CAT-lab) during preparation for the procedure. Second and third laser treatment were given 24 h and 3-days post admission ( Figure 2 ). Laser therapy was delivered for 100 s (1J/cm 2 ) to the tibia in one leg and then to the tibia in the contralateral leg. In the NLT control groups, patients were treated in a similar fashion but the laser was not turned on. Due to the dispersion of the laser beam after transmission through the tibia bone, the beam covers the entire BM underneath the laser probe. 21 Taking into consideration the anatomy of the BM space, it is estimated that about 30% of the BM volume of the tibia bone is irradiated by the laser beam. Correlations between certain variables were estimated using Spearman's Correlations, since most of the variables did not have Gaussian distributions. A two-sided P <0.05 was considered statistically significant. The data were analyzed using BMDP Statistical Software.
| Statistical analysis
3 | RESULTS
| Patient characteristics
The baselines characteristics are summarized in Table 1 . Twenty-four patients (21 males and 3 females) were recruited. The mean age was 60
and 54 in the LLLT and NLT groups respectively. A higher proportion of patients in the NLT (41.6%) group had a previous history of hypertension compared to the LLLT group (33.3%, P = 0.02). There were no other significant differences in baseline risk factors between the LLLT and NLT groups. A sudden presentation without a prodromal of chest pain was similar in the LLLT (58.3%) and NLT (41.6%) groups.
On admission, all the patients had normal myocardial biomarker values.
No significant differences were observed in the ischemic time (chest pain onset to wire crossing the lesion) and the door to balloon time (D2B: time from admission to the hospital to wire crossing the lesion).
The ischemic time was 196 ± 3 vs 188 ± 7 min (P = 0.93) and the D2B was 41 ± 8 and 48 ± 1 min (P = 0.73) in the LLLT group and in the NLT group, respectively.
| Laboratory analysis
At day one and at each consecutive day thereafter during the first 5-days post STEMI, leukocyte and platelet densities in the circulating blood were not statistical different from admission levels in both the LLLT or NLT groups.
The peak level of Troponin-T in the blood at 8-10 h after STEMI was 52% lower in the LLLT group compared to the NLT group (P < 0.05; 
| DISCUSSION
The results of the present study demonstrate that LLLT applied to the BM in patients with STEMI undergoing PPCI was feasible, safe and easily implemented. Importantly, LLLT therapy applied before reperfusion and as an adjunct to PPCI did not increase D2B times.
Furthermore, LLLT did not alter circulating leukocyte and platelet counts after STEMI. LLLT reduced the rise in Troponin-T and did not adversely affect LVEF up to 9-month following STEMI.
LLLT has been safely studied in various animal models. In a previous study, we had demonstrated the safety of LLLT application to the BM in healthy mice over almost their entire lifespan. 21 Moreover, using the infarcted porcine model, multiple laser treatment to the BM had no adverse effects when compared to control non-treated porcine. 19 The results of this trial corroborate these findings and extend its safety into human subjects.
The results of the current study also indicate a possible cardioprotective effect of LLLT exerted on the BM prior to reperfusion.
There was a significant 52% reduction in the peak Troponin-T levels after LLLT. A similar non-significant 56% reduction was also noted in the CPK accumulation with LLLT. These results are in accordance with our previous results in the infarcted porcine heart wherein laser application to the BM significantly reduced circulating Troponin-T and CPK in the blood after induction of AMI. 19 These findings must however, be interpreted in the context of a heterogeneous and small sample of patients with varying infarct locations.
In laser treated porcine models, significant improvements in LVEF were observed as early as 2 h after myocardial infarction. This rapid improvement in LVEF after AMI suggests an initial cardioprotective effect mitigated by laser application to the BM. Similar findings have been reported after direct application of LLLT to the myocardium of rats and dogs and to cardiomyocytes in vitro. 11-14 Although we did not observe a significant difference in LVEF with LLLT, LVEF improved to a similar degree in the LLLT and NLT groups. It may therefore be postulated that we were underpowered to determine significant differences in clinical parameters after STEMI, yet LLLT in humans may reduce scarring and infarct size and lead to improvements in LVEF after STEMI.
The mechanism by which LLLT applied to the BM exerts its cardioprotective effects in humans after AMI is not clearly understood.
We postulate that LLLT induces various cells types in the BM to proliferate, and under appropriate conditions, migrate to ischemic zones in the heart. Thereafter, these cells may directly exert beneficial effects or indirectly stimulate endogenous cardiac stem cells. Multiple studies in animal models are supportive of this hypothesis. Firstly, after cardiac ischemia in animals 22 and humans, 23 
